About The Study: In this study, major adverse cardiovascular event risk varied significantly by medication class, with most protection achieved with sustained treatment with glucagon-like peptide-1 ...

First-in-class drugs can be highly innovative because of their novel mechanisms of action, but they also carry uncertainty in the absence of clinical experience. To understand how such drugs advance ...